查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1510440

放射治療市場- 按放射性同位素（碘131、碘123、鎵68、镥177、18F 與Y-90）、方法（標靶治療、標靶診斷）、應用（腫瘤學、非腫瘤學）、全球預測（ 2024 - 2032）

Radiotheranostics Market - By Radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90), Approach (Targeted Therapeutic, Targeted Diagnostic), Application (Oncology, Non-Oncology), Global Forecast (2024 - 2032)
出版日期: | 出版商: Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計從2024 年到2032 年，放射治療市場規模將以超過14.6% 的複合年成長率成長。激增。根據世界衛生組織的數據，2022 年估計將報告 2,000 萬例新增癌症，導致 970 萬人死亡。不斷成長的老年人口更有可能患上癌症，這將進一步推動對放射治療的需求，因為老年人需要更頻繁的檢查和個人化治療。

創新影像和醫用放射性藥物的開發將提高診斷和治療的準確性，從而提高醫療保健提供者和患者的採用率。尖端技術和醫療需求之間不斷加強的合作也將有助於市場的成長。

放射治療產業分為放射性同位素、方法、應用和區域。

根據方法，預計到 2032 年，標靶診斷領域的市場價值將以 14.2% 的複合年成長率成長，因為它能夠為各種疾病提供個人化和精確的診斷。標靶診斷利用生物標記和分子標靶及早發現疾病，實現個人化治療並減少不必要的手術和醫療費用。醫療保健提供者和患者對個人化診斷也越來越感興趣，從而刺激了該細分市場的成長。

非腫瘤領域的放射治療市場預計在 2024 年至 2032 年期間將成長 13.9%。放射治療技術的進步提高了人們對放射治療和管理各種非腫瘤疾病的能力的認知，包括神經系統疾病、心血管疾病和內分泌疾病。這種多功能性使放射學成為醫療保健領域的寶貴工具，推動了醫療保健提供者尋求針對各種醫療狀況的準確且經濟高效的診斷解決方案的需求。

2024 年至2032 年間，亞太地區放射治療產業規模將以15.2% 的複合年成長率顯著擴張。 （包括放射治療）的需求。此外，政府促進健康可近性和健康負擔能力的措施正在推動鼓勵新放射治療技術的研發投資，從而促進區域市場的成長。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 癌症盛行率上升
      • 放射治療學在癌症診斷和治療的應用越來越多
      • 核醫學的成長趨勢
    • 產業陷阱與挑戰
      • 放射治療學開發需要更高的成本
      • 治療診斷劑的保存期限短
  • 成長潛力分析
  • 技術景觀
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：市場估計與預測：按放射性同位素分類，2021 - 2032 年

  • 主要趨勢
  • 碘131
  • 碘123
  • 鎵68
  • 镥177
  • 18F 配備 Y-90
  • 其他放射性同位素

第 6 章：市場估計與預測：依方法，2021 - 2032

  • 主要趨勢
  • 標靶治療
  • 針對性診斷

第 7 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 腫瘤學
    • 甲狀腺癌
    • 神經內分泌腫瘤
    • 肝細胞癌
    • 攝護腺癌
    • 其他腫瘤學應用
  • 非腫瘤學
    • 神經系統疾病
    • 關節炎
    • 其他非腫瘤學應用

第 8 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 9 章：公司簡介

  • Life Healthcare Group
  • Nordic Nanovector ASA
  • Novartis AG
  • Progenics Pharmaceuticals, Inc.
  • Q BioMed Inc .
  • QSAM Biosciences, Inc.
  • RadioMedix
  • Radiopharm Theranostics Limited
  • Telix Pharmaceuticals Limited
  • Terumo Corporation
簡介目錄
Product Code: 8785

Radiotheranostics market size is anticipated to grow at over 14.6% CAGR from 2024 to 2032. As the incidence of cancer increases worldwide, the demand for advanced diagnostic and treatment solutions, including radiation therapy, is significantly surging. As per WHO, in 2022, an estimated 20 million new cancer were reported, resulting in 9.7 million deaths. The growing elderly population, which is more likely to develop cancer, will further drive the demand for radiotheranostics as the elderly require more frequent examinations and individualized treatments.

The development of innovative imaging and medical radiopharmaceuticals will improve the accuracy of diagnosis and treatment, increasing adoption by healthcare providers and patients. The growing collaboration between cutting-edge technologies and medical needs will also contribute to the market growth.

The radiotheranostics industry is classified into radioisotope, approach, application and region.

Based on approach, the market value from the targeted diagnostics segment is anticipated to grow at 14.2% CAGR through 2032, due to its ability to provide personalized and precise diagnosis for various diseases. Targeted diagnostics utilize biomarkers and molecular targets to detect diseases early, enabling personalized treatment and reducing unnecessary procedures and healthcare costs. Healthcare providers and patients are also increasingly interested in personalized diagnostics, spurring the segment growth.

Radiotheranostics market from the non-oncology segment is poised to witness 13.9% growth rate during 2024-2032. Advancements in radiation therapy technologies have increased awareness of the ability of radiation to treat and manage a variety of non-oncology diseases, including neurological diseases, cardiovascular diseases, and endocrine diseases. This versatility has made radiology a valuable tool in healthcare, driving demand among healthcare providers seeking accurate and cost-effective diagnostic solutions for a variety of medical conditions.

Asia Pacific radiotheranostics industry size will record notable expansion at 15.2% CAGR between 2024 and 2032. The rising prevalence of chronic diseases, along with improved healthcare infrastructure and higher incomes is driving the demand for diagnostic and treatment methods across the region, including radiotherapy. Moreover, government initiatives to promote health access and health affordability are driving R&D investments that encourage new radiotherapy technologies, adding to the regional market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence of cancer
      • 3.2.1.2 Growing use of radiotheranostics in cancer diagnosis and management
      • 3.2.1.3 Increasing trend of nuclear medicine
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Requirement of higher cost for radiotheranostics development
      • 3.2.2.2 Short shelf life of theranostic agents
  • 3.3 Growth potential analysis
  • 3.4 Technological landscape
  • 3.5 Regulatory landscape
  • 3.6 Porter's analysis
  • 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Competitive positioning matrix
  • 4.4 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Radioisotope, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Iodine-131
  • 5.3 Iodine-123
  • 5.4 Gallium-68
  • 5.5 Lutetium-177
  • 5.6. 18F with Y-90
  • 5.7 Other radioisotopes

Chapter 6 Market Estimates and Forecast, By Approach, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Targeted therapeutic
  • 6.3 Targeted diagnostic

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oncology
    • 7.2.1 Thyroid cancer
    • 7.2.2 Neuroendocrine tumors
    • 7.2.3 Hepatocellular carcinoma
    • 7.2.4 Prostate cancer
    • 7.2.5 Other oncology applications
  • 7.3 Non-oncology
    • 7.3.1 Neurological disorders
    • 7.3.2 Arthitis
    • 7.3.3 Other non-oncology applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Italy
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Rest of Asia Pacific
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Argentina
    • 8.5.3 Mexico
    • 8.5.4 Rest of Latin America
  • 8.6 Middle East and Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

  • 9.1 Life Healthcare Group
  • 9.2 Nordic Nanovector ASA
  • 9.3 Novartis AG
  • 9.4 Progenics Pharmaceuticals, Inc.
  • 9.5 Q BioMed Inc .
  • 9.6 QSAM Biosciences, Inc.
  • 9.7 RadioMedix
  • 9.8 Radiopharm Theranostics Limited
  • 9.9 Telix Pharmaceuticals Limited
  • 9.10 Terumo Corporation